{"id":"tp-31293","type":"article-newspaper","title":"BioNTech Shares Fall 6% After BNT113 Trial Misses Key Endpoint","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/31293","datePublished":"2026-10-13T15:48:39.000Z","dateModified":"2026-10-13T15:48:39.000Z","language":"en","abstract":"The Phase 2/3 trial did not meet one of its dual primary endpoints, progression-free survival.","section":"Investing","references":[]}